GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neos Therapeutics Inc (NAS:NEOS) » Definitions » Inventories, Raw Materials & Components

Neos Therapeutics (Neos Therapeutics) Inventories, Raw Materials & Components : $2.79 Mil (As of Sep. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Neos Therapeutics Inventories, Raw Materials & Components?

Neos Therapeutics's inventories, raw materials & components for the quarter that ended in Sep. 2020 was $2.79 Mil.

Neos Therapeutics's quarterly raw materials declined from Mar. 2020 ($3.72 Mil) to Jun. 2020 ($3.56 Mil) and declined from Jun. 2020 ($3.56 Mil) to Sep. 2020 ($2.79 Mil).

Neos Therapeutics's annual raw materials increased from Dec. 2017 ($3.48 Mil) to Dec. 2018 ($3.85 Mil) but then declined from Dec. 2018 ($3.85 Mil) to Dec. 2019 ($3.68 Mil).


Neos Therapeutics Inventories, Raw Materials & Components Historical Data

The historical data trend for Neos Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neos Therapeutics Inventories, Raw Materials & Components Chart

Neos Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Inventories, Raw Materials & Components
Get a 7-Day Free Trial 1.21 1.67 3.48 3.85 3.68

Neos Therapeutics Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.37 3.68 3.72 3.56 2.79

Neos Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Neos Therapeutics (Neos Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
2940 N. Highway 360, Grand Prairie, TX, USA, 75050
Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In addition, it also manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough. Geographically, it operates through the United States and derives revenue through the sale of products.
Executives
Alan L Heller director BAXTER INTERNATIONAL INC ONE BAXTER PKWY DF2-2W DEERFIELD IL 60015
Gregory J Robitaille director
John P. Schmid director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Beth Hecht director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Linda M Szyper director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
Gerald W. Mclaughlin director, officer: Chief Executive Officer 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Richard I Eisenstadt officer: Chief Financial Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John M Limongelli officer: SVP & General Counsel 700 PENNSYLVANIA DRIVE, EXTON PA 19341
Thomas P Mcdonnell officer: Chief Commercial Officer C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050
Vipin K Garg officer: Chief Executive Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Dorothy Engelking officer: VP, Regulatory Affairs C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Juergen Martens officer: Chief Tech/Operations Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355